Peterson Kevin, Rowland-Jones Sarah
Institute for Tropical Medicine, Antwerp, Belgium.
Antivir Ther. 2012;17(3):435-8. doi: 10.3851/IMP2031. Epub 2012 Jan 25.
Many of the antiretrovirals used against HIV-1 are either ineffective or less effective in HIV-2 infection. There is in vitro evidence of the potency of maraviroc and several investigational agents against HIV-2. We conclude that, whilst specific boosted protease inhibitors combined with nucleoside analogues should still be considered the mainstays of HIV-2 treatment, maraviroc, T-1249, TAK-779 and AMD3100, as well as raltegravir, could contribute to regimens for treatment-experienced individuals. Factors bearing on the use and timing of these alternative agents are discussed.
许多用于抗HIV-1的抗逆转录病毒药物对HIV-2感染要么无效，要么效果较差。有体外证据表明马拉维若和几种研究药物对HIV-2有活性。我们得出结论，虽然特定的增效蛋白酶抑制剂联合核苷类似物仍应被视为HIV-2治疗的主要手段，但马拉维若、T-1249、TAK-779和AMD3100以及拉替拉韦，可用于有治疗经验个体的治疗方案。文中讨论了与这些替代药物的使用和时机相关的因素。
